SINT

Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced the availability of a Company-sponsored Masterclass hosted by Orthopedics This Week (“OTW”), the most widely read publication in the orthopedics industry, that brings together three industry experts to present arguments examining the value of silicon nitride over legacy implant materials and to increase awareness of the impact it may have in orthopedic applications.

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C.

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders' equity of $2.5 million. Based on SINTX's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, Nasdaq determined that the Company complies with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and confirmed that the previously disclosed deficiency matter is now closed.

SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.

SALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m.

SALT LAKE CITY, Utah, July 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting (“Southern Metrics”) to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value. Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025. Southern Metrics will establish and manage the Company's newly created Strategic Opportunity Management Program.

SALT LAKE CITY, Utah, June 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it has received purchase orders from multiple contract manufacturing customers with an aggregate value exceeding $3.2 million for the production of advanced ceramic components. SINTX's advanced ceramic manufacturing platform supports customers across multiple industries requiring high-performance materials with demanding mechanical, thermal, and chemical properties.

SALT LAKE CITY, Utah, June 03, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today announced that it has entered into securities purchase agreements with institutional and accredited investors pursuant to which the Company agreed to issue and sell an aggregate of 1,882,845 shares of common stock in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors (i) Class A Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock and (ii) Class B Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock.

Salt Lake City, Utah--(Newsfile Corp. - May 17, 2026) - SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX" or the "Company"), a medical technology company focused on advanced ceramics and silicon nitride biomaterials, today announced that management will present at the LD Micro Invitational XVI Conference in Los Angeles, California, at the Luxe Sunset Blvd Hotel. During the presentation, management expects to discuss recent progress in commercialization, product development, and manufacturing initiatives supporting the Company's silicon nitride biomaterials platform, including applications in orthopedics, spine, foot and ankle, and patient-specific implant markets.